OnKure Therapeutics, Inc. — fact timeline

OnKure Therapeutics, Inc. shareholders approved Approval of the Amended and Restated 2024 Equity Incentive Plan at the 2026-06-03 meeting.

“For Against Abstentions Broker Non-Votes 16,431,575 3,490,523 1,895 5,466,123”

OnKure Therapeutics, Inc. shareholders approved Ratification of the selection of KPMG LLP as independent registered public accounting firm at the 2026-06-03 meeting.

“For Against Abstentions Broker Non-Votes 25,329,425 60,370 321 -”

OnKure Therapeutics, Inc. shareholders approved Election of Class II directors at the 2026-06-03 meeting.

“R. Michael Carruthers 19,776,757 147,236 5,466,123 Valerie M. Jansen, M.D., Ph.D. 17,796,919 2,127,074 5,466,123 Edward T. Mathers 19,855,396 68,597 5,466,123”

OnKure Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.

“OnKure Therapeutics, Inc. issued a press release reporting financial results for the quarter ended March 31, 2026.”

OnKure Therapeutics, Inc. issued pre-funded warrants to purchase 9,430,959 shares of Common Stock of warrant to institutional accredited investors for $4.1499 per underlying Warrant Share.

“pre-funded warrants (the “Pre-Funded Warrants” and together with the Shares, the “Securities”) to purchase 9,430,959 shares of Common Stock (the “Warrant Shares”), at a purchase price of $4.1499 per underlying Warrant Share”

OnKure Therapeutics, Inc. issued 26,713,636 shares of common stock to institutional accredited investors for $4.15 per Share.

“the Company agreed to issue and sell to the Investors in a private placement (i) 26,713,636 shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $4.15 per Share”

OnKure Therapeutics, Inc. entered into Registration Rights Agreement with the Company and the Investors (effective 2026-03-27).

“the Company and the Investors also entered into a Registration Rights Agreement, dated March 27, 2026 (the “Registration Rights Agreement”), providing for the registration for resale of the Shares and the Warrant Shares, pursuant to a registration statement (the “Registration Statement”) to be filed with the SEC within 30 days after the Closing Date.”

OnKure Therapeutics, Inc. entered into Purchase Agreement with certain institutional accredited investors valued at approximately $150.0 million (effective 2026-03-27).

“On March 27, 2026, OnKure Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (i) 26,713,636 shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $4.15 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants” and together with the Shares, the “Securities”) to purchase 9,430,959 shares of Common Stock (the “Warrant Shares”), at a purchase price of $4.1499 per underlying Warrant Share (the “Private Placement”).”

OnKure Therapeutics, Inc. reported the fourth quarter ended December 31, 2025 results: net income $13.5 million, EPS $0.99 per share.

“Net loss and net loss per share for the fourth quarter of 2025 were $13.5 million, or $0.99 per share”

OnKure Therapeutics, Inc. engaged KPMG LLP as its auditor.

“On November 7, 2024, the Audit Committee engaged KPMG as the independent registered public accounting firm of the Company.”

OnKure Therapeutics, Inc. dismissed Ernst & Young LLP as its auditor.

“On November 7, 2024, Ernst & Young LLP ("EY") was dismissed as the independent registered public accounting firm of OnKure Therapeutics, Inc. (formerly Reneo Pharmaceuticals, Inc.) (the "Company").”

OnKure Therapeutics, Inc.: Reneo ceased to be a shell company as a result of the Transactions.

“As a result of the Transactions, Reneo ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) upon the Closing.”

OnKure Therapeutics, Inc.: Adoption of a new Code of Business Conduct and Ethics applicable to all employees, officers and directors.

“In connection with the Transactions, the Board approved and adopted a new Code of Business Conduct and Ethics applicable to all employees, officers and directors of the Company.”

OnKure Therapeutics, Inc.: Amendment and restatement of bylaws updating stockholder meeting procedures, director nomination requirements, board meeting provisions, indemnification, and other updates (effective 2024-10-04).

“On October 4, 2024, in connection with the Merger, the Board approved the amendment and restatement of the Company’s bylaws, effective as of October 4, 2024”

OnKure Therapeutics, Inc.: Amended and restated certificate of incorporation to change name to OnKure Therapeutics, Inc., create Class B Common Stock, reclassify Reneo common stock as Class A Common Stock (effective 2024-10-04).

“The amended and restated certificate of incorporation became effective at 4:02 p.m. on October 4, 2024.”

Andrew Phillips was appointed as Chair of the Board at OnKure Therapeutics, Inc..

“Also on October 4, 2024, Andrew Phillips, Ph.D. was appointed as the Chair of the Board.”

Michael Grey was appointed as Class III Director at OnKure Therapeutics, Inc..

“Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.”

Andrew Phillips was appointed as Class III Director at OnKure Therapeutics, Inc..

“Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.”

Edward T. Mathers was appointed as Class II Director at OnKure Therapeutics, Inc..

“Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.”

Valerie M. Jansen was appointed as Class II Director at OnKure Therapeutics, Inc..

“Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.”

R. Michael Carruthers was appointed as Class II Director at OnKure Therapeutics, Inc..

“Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.”

Isaac Manke was appointed as Class I Director at OnKure Therapeutics, Inc..

“Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.”

Nicholas Saccomano was appointed as Class I Director at OnKure Therapeutics, Inc..

“Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.”

Ashley F. Hall was terminated as Chief Development Officer at OnKure Therapeutics, Inc..

“the Company terminated the employment of Ashley F. Hall, J.D., the Company’s Chief Development Officer, effective as of September 13, 2024.”

OnKure Therapeutics, Inc. entered into Merger Agreement with Reneo Pharmaceuticals, Inc. (effective 2024-05-10).

“On May 10, 2024, Reneo Pharmaceuticals, Inc., a Delaware corporation (“ Reneo ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Reneo (“ Merger Sub I ”), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Reneo (“ Merger Sub II ”), and OnKure, Inc., a Delaware corporation (“ OnKure ”)”

Ashley F. Hall departed as other_named_officer at OnKure Therapeutics, Inc..

“each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.”

Alejandro Dorenbaum departed as other_named_officer at OnKure Therapeutics, Inc..

“each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.”

Gregory J. Flesher departed as other_named_officer at OnKure Therapeutics, Inc..

“each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.”

OnKure Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income net loss of $8.4 million, or $0.25 per share, EPS $0.25 per share.

“We reported a net loss of $8.4 million, or $0.25 per share, during the first quarter of 2024, compared to a net loss of $15.1 million, or $0.60 per share, for the same period in 2023.”

OnKure Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2023 results: net income $23.6 million (fourth quarter) and $77.4 million (full year), EPS $0.70 per share (fourth quarter) and $2.52 per share (full year).

“Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.”

OnKure Therapeutics, Inc. announced a restructuring with charges of approximately $1.7 million (approximately 20%).

“the Company expects to complete a second workforce reduction of approximately 20% on February 29, 2024 (the “Second Reduction”). In connection with the Second Reduction, the Company estimates that it will incur charges of approximately $1.7 million associated with cash severance payments and other employee termination-related costs in the first quarter of 2024.”

OnKure Therapeutics, Inc. announced a restructuring with charges of approximately $2.5 million.

“the Company estimates that it will incur charges of approximately $2.5 million associated with cash severance payments and other employee termination-related costs in the fourth quarter of 2023.”

OnKure Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income net loss of $19.2 million, or $0.57 per share, EPS $0.57 per share.

“Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the third quarter ended September 30, 2023”

OnKure Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income net loss of $19.5 million, or $0.65 per share, EPS $0.65 per share.

“On August 10, 2023, Reneo Pharmaceuticals, Inc. (the “Company”) issued a press release reporting the Company’s financial results for the second quarter ended June 30, 2023”

OnKure Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-06 meeting.

“Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results are as follows: For Against Abstain Broker Non-Votes 20,316,020 12,633 100 -”

OnKure Therapeutics, Inc. shareholders approved Election of Directors at the 2023-06-06 meeting.

“Proposal 1. Election of Directors The Company’s stockholders elected the three persons listed below as Class III directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows: For Abstain Broker Non-Votes Edward T. Mathers 15,749,259 815,951 3,763,543 Bali Muralidhar, M.D., Ph.D. 15,423,901 1,141,309 3,763,543 Stacey D. Seltzer 15,937,901 627,309 3,763,543”

OnKure Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income net loss of $15.1 million, EPS $0.60 per share.

“We reported a net loss of $15.1 million, or $0.60 per share, during the first quarter of 2023, compared to a net loss of $13.0 million, or $0.53 per share, for the same period in 2022.”

OnKure Therapeutics, Inc. entered into Securities Purchase Agreement with Abingworth Bioventures 8 LP valued at 625,000 shares of common stock at $8.00 per share; total purchase price approx. $5.0 million (effective 2023-05-02).

“On May 2, 2023, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Abingworth Bioventures 8 LP. (“Abingworth”).”

OnKure Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters valued at 6,875,000 shares of common stock at $8.00 per share; additional 1,031,250 shares option exercised; n (effective 2023-05-03).

“On May 3, 2023, Reneo Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters listed on Schedule A thereto (collectively, the “Underwriters”), relating to an offering (the “Public Offering”) of 6,875,000 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (“Common Stock”).”

OnKure Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2022 results: net income net loss of $13.6 million, or $0.56 per share, during the fourth quarter of 2022.

“We reported a net loss of $13.6 million, or $0.56 per share, during the fourth quarter of 2022, compared to a net loss of $10.6 million, or $0.43 per share, for the same period in 2021. For the full year 2022, we reported a net loss of $52.0 million, or $2.12 per share, compared to a net loss of $39.8 million, or $2.19 per share, for the full year 2021.”

OnKure Therapeutics, Inc. reported the three months ended September 30, 2022 results: net income $13.0 million, EPS $0.53 per share.

“The Company reported a net loss of $13.0 million, or $0.53 per share, for the three months ended September 30, 2022”

Roshawn Blunt was appointed as Class I Director at OnKure Therapeutics, Inc..

“appointed Roshawn Blunt as a Class I director of the Company, with a term of office expiring at the 2025 annual meeting of stockholders.”

Jennifer P. Lam was appointed as principal financial and accounting officer at OnKure Therapeutics, Inc..

“On March 2, 2022, the Board appointed Jennifer P. Lam, the Company’s Vice President of Finance & Administration, as the Company’s principal financial and accounting officer, effective March 31, 2022 (the “Lam Appointment”).”

Michael P. Cruse was appointed as Chief Operating Officer at OnKure Therapeutics, Inc..

“On March 2, 2022, the Board of Directors (the “Board”) of Reneo Pharmaceuticals, Inc. (the “Company”) appointed Michael P. Cruse as the Company’s Chief Operating Officer, effective immediately (the “Cruse Appointment”).”

Vineet R. Jindal resigned as Chief Financial Officer at OnKure Therapeutics, Inc..

“On January 28, 2022, Vineet R. Jindal notified Reneo Pharmaceuticals, Inc. (the “Company”) of his intention to resign from his position as the Company’s Chief Financial Officer, effective as of March 31, 2022 (the “Separation Date”).”

Kenneth Harrison resigned as Director at OnKure Therapeutics, Inc..

“On January 20, 2022, Kenneth Harrison, Ph.D. resigned from the Board to focus on other endeavors.”

Lon Cardon departed as Class I Director at OnKure Therapeutics, Inc..

“On January 18, 2022, Lon Cardon, Ph.D. informed the Company that he will not stand for re-election as a member of the Board when his term as a Class I director expires at the Company’s 2022 annual meeting of stockholders.”

Paul Hoelscher was appointed as Class I Director and Audit Committee Chair at OnKure Therapeutics, Inc..

“On January 20, 2022, the Board of Directors (the “Board”) of Reneo Pharmaceuticals, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Paul Hoelscher as (i) a Class I director of the Company, with a term of office expiring at the 2022 annual meeting of stockholders, (ii) a member of the Audit Committee of the Board (the “Audit Committee”) and (iii) Chair of the Audit Committee”

Wendy Johnson resigned as Chief Business Officer at OnKure Therapeutics, Inc..

“On December 23, 2021, Reneo Pharmaceuticals, Inc. (the “Company”) entered into a Transition, Separation and Consulting Agreement (the “Agreement”) with Wendy Johnson, in connection with her previously announced resignation from the Company.”

Ashley F. Hall was appointed as Chief Development Officer at OnKure Therapeutics, Inc..

“On October 11, 2021, Reneo Pharmaceuticals, Inc. (the “Company”) announced the appointment of Ashley F. Hall, J.D., as the Chief Development Officer of the Company.”